Liposomes for protection against toxic compounds

Abstract

Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.

What is claimed is: 
     
         1 . A method of reducing effects of radiation in a subject exposed to the radiation, the method comprising the steps of selecting a subject to be exposed to or exposed to radiation and administering to the subject a proteoliposomal composition comprising a liposome and RLIP76 before or after the subject has been exposed to radiation, wherein administration reduces the effects of the radiation in the subject. 
     
     
         2 . The method of  claim 1 , wherein the RLIP76 comprises two ATP binding sites. 
     
     
         3 . The method of  claim 1 , wherein the RLIP76 comprises amino acids 1-367 of SEQ ID NO:2. 
     
     
         4 . The method of  claim 2 , wherein the RLIP76 comprises amino acids 410-655 of SEQ ID NO:2. 
     
     
         5 . The method of  claim 1 , wherein the RLIP76 comprises the amino acid sequence GKKKGK. 
     
     
         6 . The method of  claim 1 , wherein the RLIP76 comprises the amino acid sequence GGIKDLSK. 
     
     
         7 . The method of  claim 1 , wherein the RLIP76 comprises amino acids 1-367 and 410-655 of SEQ ID NO:2. 
     
     
         8 . The method of  claim 2 , wherein the first ATP binding site is located in amino acids 1-367 of SEQ ID NO:2 and the second ATP binding site is located in amino acids 410-655 of SEQ ID NO:2. 
     
     
         9 . The method of  claim 1 , wherein the RLIP76 comprises a RLIP76 GTPase-activating domain and a Ral binding domain. 
     
     
         10 . The method of  claim 1 , wherein the liposome is selected from the group consisting of lectin, glycolipid, phospholipid and combinations thereof. 
     
     
         11 . The method of  claim 1 , wherein the radiation is selected from the group consisting of therapeutic radiation, x-ray radiation, gamma radiation, ultraviolet radiation and nuclear radiation. 
     
     
         12 . The method of  claim 1 , wherein the radiation is therapeutic radiation. 
     
     
         13 . The method of  claim 1 , wherein the radiation is nuclear radiation. 
     
     
         14 . The method of  claim 1 , wherein the radiation is ultraviolet radiation. 
     
     
         15 . The method of  claim 1 , wherein the proteoliposomal composition is administered to the subject 3 days prior, 3 days after and 5 days after the radiation. 
     
     
         16 . The method of  claim 1 , wherein the proteoliposomal composition is administered to the subject prior to radiation exposure. 
     
     
         17 . The method of  claim 1 , wherein the proteoliposomal composition is administered to the subject after radiation exposure. 
     
     
         18 . The method of  claim 1 , wherein the proteoliposomal composition is administered to the subject prior to and after radiation exposure. 
     
     
         19 . The method of  claim 1 , wherein the proteoliposomal composition is administered in one dose. 
     
     
         20 . The method of  claim 1 , further comprising preparing the proteoliposomal composition by contacting the liposome with RLIP76 or a portion thereof.